GHK-Cu vs Minoxidil
Well Studied vs FDA Approved
compatible GHK-Cu is a copper peptide that supports tissue remodeling, wound healing, and may promote hair follicle health. No known negative interactions with minoxidil. Some users incorporate both into their hair care regimen for complementary follicular support.
Molecular Data
GHK-Cu Minoxidil
Weight 404.96 Da 209.25 Da
Half-life 0.5-2 hours ~4 hours (oral); topical effects persist significantly longer due to local tissue retention
Chain 3 amino acids —
Type Copper tripeptide Synthetic pyrimidine derivative (6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine)
Key Benefits
GHK-Cu
01 Enhanced collagen production (70% increase in type I and III)
02 Improved skin elasticity
03 Reduced fine lines and wrinkles
04 Accelerated wound healing
05 Hair growth stimulation
06 Antioxidant protection
Minoxidil
01 FDA-approved for androgenetic alopecia with decades of clinical evidence
02 Stimulates new hair growth and increases hair follicle size independent of androgen pathways
03 Available over the counter as a topical treatment without a prescription
04 Effective in both men and women for pattern hair loss
05 Low-dose oral formulation offers a convenient once-daily alternative to twice-daily topical application
06 Synergistic with finasteride and dutasteride for a multi-mechanism approach to hair loss
07 Extends the anagen (growth) phase and shortens the telogen (resting) phase of the hair cycle
Dosing Protocols
GHK-Cu
0.5-2% topical or 1-3mg injectable / 1-2x daily
Systemic anti-aging 1-2mg 1x daily
Enhanced regeneration 2-3mg 1-2x daily
Minoxidil
Topical: 1mL of 5% solution twice daily / Oral: 1.25-2.5mg daily / Twice daily (topical) or once daily (oral)
Side Effects
GHK-Cu
Mild skin irritation initially (usually resolves)
Increased photosensitivity
Minoxidil
Scalp irritation, dryness, or flaking (topical, especially solution formulations containing propylene glycol)
Initial shedding phase during the first 1-3 months of treatment
Hypertrichosis (unwanted facial and body hair growth, more common with oral administration)
Fluid retention and mild peripheral edema (oral)
Mild dizziness or lightheadedness upon standing (oral, due to vasodilation)
Contraindications
Known copper sensitivity or Wilson's disease
Active skin infections at application site
Pregnancy or breastfeeding (injectable)
Known hypersensitivity to minoxidil or any component of the formulation
Pheochromocytoma (minoxidil may stimulate catecholamine release)
Significant cardiovascular disease, including history of pericardial effusion or congestive heart failure
Concurrent use of potent antihypertensive medications without physician supervision (risk of additive hypotension)
Pregnancy and breastfeeding (Category C; oral minoxidil has shown evidence of fetal harm in animal studies)
Research Evidence
GHK-Cu Minoxidil
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest July 2025 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.